Reducing the dose of smallpox vaccine reduces vaccine-associated morbidity without reducing vaccination success rates or immune responses

Journal of Infectious Diseases

Volumn 195, Issue 6, 2007, Pages 826-832

  Couch, Robert B ^a   Winokur, Patricia ^b   Edwards, Kathryn M ^c   Black, Steven ^d   Atmar, Robert L ^a   Stapleton, Jack T ^b   Kissner, Jannifer M ^c   Shinefield, Henry ^d   Denny, Thomas N ^e   Bybel, Michael J ^f   Newman, Frances K ^g   Yan, Lihan ^h  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d KAISER PERMANENTE   (United States)

^e UNIVERSITY OF MEDICINE AND DENTISTRY   (United States)

^f SANOFI PASTEUR   (France)

^g SAINT LOUIS UNIVERSITY   (United States)

^h EMMES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; SMALLPOX VACCINE; SPSV 2243; SPSV 2248; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELUSION; DILUTION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MANUFACTURE; ERYTHEMA; FATIGUE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MORBIDITY; MYALGIA; MYOPIA; NAUSEA; PRIORITY JOURNAL; SKIN DEFECT; SKIN INDURATION; SMALLPOX; TREATMENT OUTCOME; UNITED STATES; VACCINE PRODUCTION;

ADOLESCENT; ADULT; ALLANTOIS; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CHICK EMBRYO; CHORION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; SMALLPOX VACCINE; TREATMENT OUTCOME; VARIOLA VIRUS;

EID: 33847625458     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/511828     Document Type: Article

References (26)

1. Henderson DA, Inglesby TV, Bartlett JH, et al. Smallpox as a biological weapon: medical and public health management. JAMA 1999; 281:2127-37.
2. Rotz LD, Dotson DA, Damon IK, Betcher JA, Advisory Committee on Immunization Practices. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Morb Mortal Wkly Rep 2001; 50(RR-10):1-25.
3. Frey SE, Couch RB, Tacket CO, et al. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 2002; 346:1265-74.
4. Talbot TR, Stapleton JT, Brady RC, et al. Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: a randomized controlled trial. JAMA 2004; 292:1205-12.
5. Newman FK, Frey SE, Blevins TP, Yan L, Belshe RB. Stability of undiluted and diluted vaccinia-virus vaccine, Dryvax. I Infect Dis 2003; 187:1319-22.
6. Manischewitz J, King LR, Bleckwenn NA, et al. Development of a novel vaccinia-neutralization assay based on reporter-gene expression. J Infect Dis 2003; 188:440-8.
7. Chakrabarti S. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 1997; 23:1094-7.
8. Crittenton E, Davis A, Hoffmann KK, Rutala WA, Weber DJ. Semi-permeable dressing used to cover smallpox vaccination sites as a cause of skin damage. Infect Control Hosp Epidemiol 2004; 25:96.
9. Belshe RB, Newman FK, Frey SE, Couch RB, Treanor JJ, Tacket CO. Dose-dependent neutralizing-antibody responses to vaccinia. J Infect Dis 2004; 189:493-7.
10. Grabenstein JD, Winkenwerder W Jr. US military smallpox vaccination program experience. JAMA 2003; 289:3278-82.
11. Hsieh S-M, Chen S-Y, Sheu G-C, et al. Clinical and immunological responses to undiluted and diluted smallpox vaccine with vaccinia virus of Lister strain. Vaccine 2006; 24:510-5.
12. Kirn S-H, Yeo S-G, Jang H-C, et al. Clinical responses to smallpox vaccine in vaccinia-naive and previously vaccinated populations: undiluted and diluted Lancy-vaxina vaccine in a single-blind, randomized, prospective trial. J Infect Dis 2005; 192:1066-70.
13. Cockburn WC, Cross RM, Downie AW, et al. Laboratory and vaccination studies with dried smallpox vaccines. Bull World Health Organ 1957; 16:63-77.
14. Espmark JA. Smallpox vaccination studies with serial dilutions of vaccine. Acta Pathol Microbiol Scand 1965; 63:97-115.
15. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. Smallpox vaccination: a review. Part I. Background, vaccination technique, normal vaccination and revaccination, and expected normal reactions. Clin Infect Dis 2003; 37:241-50.
16. Bartlett J, Borio L, Radonovich L, et al. Smallpox vaccination in 2003: key information for clinicians. Clin Infect Dis 2003; 36:883-902.
17. Frey SE, Newman FK, Yan L, Belshe RB. Response to smallpox vaccine in persons immunized in the past. JAMA 2003; 289:3295-9.
18. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: national surveillance in the United States. N Engl J Med 1969; 281:1201-8.
19. Espmark JA. Smallpox vaccination studies with serial dilutions of vaccine. IV. Graded local responses and fever reactions following primary vaccination in children. Acta Paediatr Scand 1965; 54:239-46.
20. Cherry JD, McIntosh K, Connor JD, et al. Primary percutaneous vaccination. J Infect Dis 1977; 135:145-54.
21. Frey SE, Newman FK, Cruz J, et al. Dose-related effects of smallpox vaccine. N Engl J Med 2002; 346:1275-80.
22. Moore ZS, Seward JF, Lane JM. Smallpox. Lancet 2006; 367:425-35.
23. Greenberg RN, Kennedy JS, Clanton DJ, et al. Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial. Lancet 2005; 365:398-409.
24. Artenstein AW, Johnson C, Marbury TC, et al. A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine 2005; 23:3301-9.
25. McCurdy LH, Larkin BD, Martin JE, Graham BS. Modified vaccinia Ankara: potential as an alternative smallpox vaccine. Clin Infect Dis 2004; 38:1749-53.
26. Cebere I, Dorrell L, McShane H, et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected subjects. Vaccine 2006; 24:417-25.